Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

In Memoriam: Nobel Laureate James D. Watson, Ph.D. (1928-2025)

November 11, 2025 by sjwilliamspa

In Memoriam: Nobel Laureate James D. Watson, Ph.D. (1928-2025)

Curator: Stephen J. Williams, Ph.D.

On Thursday November 6, 2025, Nobel Laureate Dr. James D. Watson passed away after a reported brief illness.  Although well known for his discovery of the DNA double helix with Francis Crick, Maurice Wilkens using the crystallographic data of Rosalind Franklin, Dr. Watson had contributed other seminal findings to the fields of biology and cancer, as well as his mentoring of young scientists.  Therefore  it is only fitting to curate some of the commentary on his life and passing in the words of the institutions and the renowned scientists he had mentored.

The world of science bids farewell to one of its most brilliant and controversial figures, Dr. James Dewey Watson, who passed away on 6th November 2025 at the age of 97. Best known as one of the co-discoverers of the double-helix structure of DNA, Watson’s name became synonymous with a new era in genetics and molecular biology. His life, filled with intellectual daring, unyielding curiosity, and deep contributions to science and education, forever altered humanity’s understanding of the genetic code that defines life itself.

James Watson and Francis Crick with model of DNA double helix. The model was based on data from Rosalind Franklin and x ray diffraction analysis of Maurice Wilkins.

From Cold Spring Harbor Laboratory, where Dr. Watson spent most of his scientific career:

Jim Watson made many contributions to science, education, public service, and especially Cold Spring Harbor Laboratory (CSHL).

As a scientist, his and Francis Crick’s determination of the structure of DNA, based on data from Rosalind Franklin, Maurice Wilkins and their colleagues at King’s College London, was a pivotal moment in the life sciences. Watson, along with Crick and Wilkins were awarded the 1962 Nobel Prize in Physiology or Medicine. Watson also received the Presidential Medal of Freedom from President Gerald Ford and the National Medal of Science from President Bill Clinton, among many other awards and prizes. While at Cambridge, Watson also carried out pioneering research on the structure of small viruses. At Harvard, Watson’s laboratory demonstrated the existence of mRNA, in parallel with a group at Cambridge, UK, led by Sydney Brenner. His laboratory also discovered important bacterial proteins that control gene expression and contributed to understanding how mRNA is translated into proteins.

As an author, Watson wrote two books at Harvard that were and remain best sellers. The textbook Molecular Biology of the Gene, published in 1965 (7th edition, 2020), changed the nature of science textbooks, and its style was widely emulated. The Double Helix (1968) was a sensation at the time of publication. Watson’s account of the events that resulted in the elucidation of the structure of DNA remains controversial, but still widely read.

As a public servant, Watson successfully guided the first years of the Human Genome Project, persuading scientists to take part and politicians to provide funding. He created the Ethical, Legal and Social Issues (ELSI) program because of his concerns about misuse of the fruits of the project.

Watson’s association with Cold Spring Harbor Laboratory began in 1947 when he came as a graduate student with his supervisor, Salvador Luria. Luria, with Max Delbruck, was teaching the legendary Phage Course. Watson returned repeatedly to CSHL, most notably in 1953 when he gave the first public presentation of the DNA double helix at that year’s annual Symposium. He became a CSHL trustee in 1965.

CSHL was created in 1964 by the merger of two institutes that existed in Cold Spring Harbor since 1890 and 1902, respectively. In 1968, Watson became the second director when he was 40 years old. John Cairns, the first director, had begun to revive the institute but it was still not far short of being destitute when Watson took charge. He immediately showed his great skills in choosing important topics for research, selecting scientists and raising funds.

Also in 1968, Watson married Elizabeth (Liz) Lewis, and they have lived on the CSHL campus their entire lives together. Jim and Liz have two sons, Rufus and Duncan. As with the former Directors, they fostered close relationships with the local Cold Spring Harbor community.

In 1969, Watson focused research at CSHL on cancer, specifically on DNA viruses that cause cancer. The study of these viruses resulted in many fundamental discoveries of important biological processes, including the Nobel prize-winning discovery of RNA splicing. Watson was the first Director of CSHL’s National Cancer Institute-designated Cancer Center, which remains today.

Watson was passionate about science education and promoting research through meetings and courses. Meetings began at CSHL in 1933 with the Symposium series, and the modern advanced courses started with the Phage course in 1945. Watson greatly expanded both programs, making CSHL the leading venue for learning the latest research in the life sciences. Publishing also increased, notably of laboratory manuals, epitomized by Molecular Cloning, and several journals began, led by Genes & Development and later Genome Research. He encouraged the creation of the DNA Learning Center, unique in providing hands-on genetic education for high-school students. There are now DNA Learning Centers throughout the world.

Through a substantial gift to CSHL in 1973 by Charles Robertson, Watson started the Banbury Center on the Robertsons’ 54-acre estate in nearby Lloyd Harbor. Today, this center functions as an important “think tank” for advancing research and policies on many issues related to life and medical sciences.

 

From the American Association for Cancer Research (AACR) and contributions to cancer research

James D. Watson, PhD

Cold Spring Harbor Laboratory
Cold Spring Harbor, New York

Class of 2013

A renowned molecular biologist, teacher, and author, Dr. Watson is best known as the co-discoverer of the double-helix structure of DNA, for which he won the 1962 Nobel Prize in Physiology or Medicine. First announced in early April 1953 by the director of the Cavendish Laboratory in Cambridge, the discovery went largely unnoticed until a paper reporting it appeared in the April 25, 1953, issue of Nature. Prominent biologists later described the finding as the most important scientific discovery of the 20th century.

Dr. Watson headed the Human Genome Project at the National Institutes of Health from 1990 to 1992. In 2007, he became the second person to publish his personal fully sequenced genome online. Ahead of his time as usual, he said he did so to “encourage the development of an era of personalized medicine”, in which information contained in our genomes can be used to identify and prevent disease and to create individualized medical therapies. – He has written several highly regarded molecular biology textbooks and in 1968 published a personal account in The Double Helix, which became one of Modern Library ‘s 100 Best Nonfiction Books.

Career Highlights

2001 Benjamin Franklin Medal for Distinguished Achievement in the Sciences
2000 The Liberty Medal, National Constitution Center
1999 Honorary Member, AACR
1997 National Medal of Science, National Science Foundation
1994-2004 President, Cold Spring Harbor Laboratory
1993 Copley Medal of the Royal Society of London
1988-1992 Director, Human Genome Project, NIH
1971 John J. Carty Award in Molecular Biology, National Academy of Sciences
1975 Elected Fellow, American Academy of Arts and Sciences
2002 Gairdner Foundation International Award
1962 Nobel Prize in Physiology or Medicine
1960 Albert Lasker Award for Basic Medical Research
1959 Eli Lilly Award in Biological Chemistry
1959 John Collins Warren Prize, Massachusetts General Hospital
1950 PhD, Indiana University, Bloomington

Source: https://www.aacr.org/professionals/membership/aacr-academy/fellows/james-d-watson-phd/?gad_source=5&gad_campaignid=21152407190&gclid=EAIaIQobChMI_JDVpozlkAMVVV1yCh2S3jjEEAAYBSAAEgKgwPD_BwE 

Read a wonderful biography on OncoDaily https://oncodaily.com/history/hall-of-fame/james-watson-and-dna

In the Words of Colleagues who Worked With Dr. James Watson

Philip Sharp

Molecular biologist Phillip Allen Sharp received the 1993 Nobel Prize in physiology or medicine for his discovery of splicing of introns and exons or “split genes.” He found that these genes are the most common type of gene structure in higher organisms, including humans. He shared the prize with Richard John Roberts, who discovered split genes independently of Sharp. The discovery of split genes has been of fundamental importance to basic research in biology as well as medical research on the development of cancer and other diseases. The discovery of split genes led to the prediction of the genetic process of splicing.

Here is a great interview with Nobel Laureate Dr. Philip Sharp and working with Jim Watson at Cold Spring Harbor Labs

Watch Video

These are the parts of the transcript he talk about working with Jim Watson.  Note he also seeked out David Baltimore to do a postdoctoral fellowship at MIT on viruses.

Transcript:

Sharp: So I also wanted to begin to work with human cells. And I wanted to work with viruses that infected human cells, because, again, I could isolate their DNA. And I could understand that DNA. And I got that experience from working with Jerry Vinograd at Caltech, who was also a professor there. And I collaborated with him and Norman once while I was there. So I wanted to learn virology. And I contacted three labs to do a second postdoc for a period of time. Dave Baltimore, who was here at MIT, Howard Temin up at Wisconsin, and Jim Watson at Cold Spring Harbor. And Jim invited me to come to Cold Spring Harbor. I moved there to start working with animal viruses. He had just come down from Harvard to take over Cold Spring Harbor and was expanding the tumor virus program there.So I joined that program and started to work with mammalian cells and DNA tumor viruses that cause tumors in animals. But to me they were a tool as well to begin to look at gene structure and function in the human cells.

INTERVIEWER: So as a humanist, for lack of a better word, you were interested on some level in the potential for the curative powers of biology by studying viruses; but as a chemist you saw viruses as this platform, a window, into the structure of DNA.

SHARP: That’s right, and the structure of cells. How the complex human cell worked. Because in the early 1970s, we really didn’t have the tools to begin to understand the biology, molecular biology, or cell biology of human cells. It was really a totally unexplored at the level of a gene and how it functioned. And I saw this as a chemist as a tool that I could move into that question. And I knew that question was central to human biology. I mean, you can’t understand the biology of an organism without understanding the gene. So it seemed pretty apparent to me. It’s sort of written on the wall, understand what the gene is. And so I, you know, had multiple reasons to begin these studies. Some was, you know, how cancer developed. Others were fundamental. What was a gene.

INTERVIEWER: Most people who’ve understood James Watson by reputation at the time that you went to study with him viewed him as a towering pillar of science who had answered an enormously important question in biology for all time. But when you went to study with him, you were, in fact, seeing it from the other side, that, in fact, Watson’s work was just the beginning of an extremely long journey that we’re still on. How did he understand that we were at the beginning of something, versus how you understood it. And how did that work in your relationship?

SHARP: Jim at that stage, you know, he had done so much. He had discovered the structure of DNA. He’d built the Department of Molecular Biology and Biochemistry at Harvard, the most outstanding department in the country focused on that. Written his text book, The Molecular Biology of the Gene, which was the introduction to students of this fascinating field. And took over Cold Spring Harbor and resurrected from a lab that was not going to survive much longer. He constructed, he understood that DNA was a critical tool in understanding complex biology. And that this subject would lead to increasing insights. He obviously had a much greater vision of all the relationships of, you know, different parts of biology to these questions than I did. And he gathered around him very bright, energetic, interesting people. And he’s sort of chit chatted at the top, left him alone. And when he found something that was interesting that happened in that mix, he would sort of pluck it out and say, “nice work”, you know. “Write that up. Tell other people about that.” And so he played that sort of, you know, very senior mentor and creator of a community. And in that community, I found some really wonderful people, very talented people. Joe Sambrook who I collaborated with. And Ulf Pettersson and Mike Botchan and a whole host of others who are now all leaders around the world. So it was just a very stimulating environment.

INTERVIEWER: Again, this sense of a team of people working at the top of their game, focused in any way they can, using all the disciplines of knowledge at their disposal on the problems that excite them.

SHARP: That’s true, and a team in which there are different disciplines. Jim understood this, that he needed someone with more physical chemistry; and he needed someone with chemistry. And he needed a biologist. And he needed this biochemist. And he sort of, you know, mixed people that would complement one another. And I was the individual who came in with a broad interest in biology, new and physical chemistry, new electron microscopy. And there was a lot of people in the environment that were virologists and cell biologists who needed this sort of tools to do their science. So we complemented each other and stimulated each other.

Sir Richard John Roberts, Ph.D.

Sir Richard John Roberts was co-awarded with Philip Sharp the 1993 Nobel Prize in Physiology or Medicine for their discovery of RNA splicing.  They both worked at Cold Spring Harbor Laboratories.  Dr. Roberts also discovered numerous restriction enzymes which he used to develop DNA sequencing of complex genomes. He also co-founded New England BioLabs. Below is an interesting interview of his quick hiring interview with Jim Watson and his time at Cold Spring Harbor Labs.

 

 

 

Other Notable Scientists Who Have been Mentored and interacted with Dr. Watson

Antonio Giordano, M.D., Ph,D.

Dr. Giordano is the President and Founder of the Sbarro Health Research Organization and Professor in Biology at Temple University and ‘chiara fama’ Professor of Anatomic Pathology in the Department of Medical Biotechnology at the University of Siena, in Siena, Italy.  He discovered the tumor suppressor RBL2/p130 and showed its alteration in multiple tumor types, showing the first molecular evidence that causually linked proliferation and cancer.  In addition he has discovered cyclin dependent kinases CDK9 and CDK10, as well as other regulators and development of new classes of inhibitors of the cell cycle.

Dr. Antonio Giordano with his mentor and colleague Dr. James Watson. Dr. James Dewey Watson discovered the structure of the DNA molecule with Francis Crick and Maurice Wilkens, whom he also received the Nobel Prize for. On the left is a signed copy to Dr. Giordano of Watson’s book the Double Helix.

 

Other articles of relevance on James Watson and the DNA Helix on this Open Access Journal include:

switching on genes

The Human Genome Gets Fully Sequenced: A Simplistic Take on Century Long Effort

The Search for the Genetic Code

International Award for Human Genome Project

Cracking the Genome – Inside the Race to Unlock Human DNA – quotes in newspapers

The Human Genome Project

Junk DNA and Breast Cancer

A Perspective on Personalized Medicine

 

 

Share this:

• X
• LinkedIn
• Facebook
• Print
• Email

Like this:

Like Loading...

Posted in Genome Biology, Nobel Prize Winners | Tagged Cold Spring Harbor Laboratory, DNA, James D. Watson, nobel leureates, Nobel Prize in Physiology and Medicine, Philip Sharp, Richard John Roberts, scientific mentorship | Leave a Comment »

News from AACR; In Memoriam: Nobel Leaureate David Baltimore, Ph.D.

November 8, 2025 by sjwilliamspa

News from AACR; In Memoriam: Nobel Leaureate David Baltimore, Ph.D.

Stephen J. Williams, Ph.D.: Reporter

Source: From AACR  Source: https://www.aacr.org/professionals/membership/in-memoriam/david-baltimore/ 

In Memoriam: David Baltimore

(03/07/1938 – 09/06/2025)Member since 2013

David Baltimore, PhD, FAACR, a Fellow of the AACR Academy and a towering figure in modern biology whose insights reshaped cancer research and biomedical science, died on September 6, 2025, at the age of 87.

Baltimore’s career was defined by transformative discoveries. In 1975, he was awarded the Nobel Prize in Physiology or Medicine, alongside Renato Dulbecco and Howard Temin, for elucidating how tumor viruses interact with the genetic material of the cell. His discovery of reverse transcriptase overturned one of the central dogmas of molecular biology by showing that genetic information could flow from RNA back to DNA. This single revelation opened countless new frontiers in virology, immunology, oncology, and genetics, laying the foundation for decades of scientific advances influencing the fundamental understanding of retroviruses such as HIV, and driving the development of modern gene therapies and mRNA-based technologies.

Following his groundbreaking work in virology, Baltimore expanded his focus to the immune system, pioneering research on how mammalian immunity can be harnessed to combat cancer. His quintessential vision and curiosity fueled entire fields of inquiry, and his scholarship bridged basic science with clinical potential.

Born in New York City in 1938, Baltimore earned his undergraduate degree from Swarthmore College and a doctorate from Rockefeller University in 1964. His early independent research at the Massachusetts Institute of Technology (MIT) and the Salk Institute quickly established him as one of the most original scientific thinkers of his generation. At just 30 years old, he became an associate professor at MIT, where he would spend much of his career shaping both science and the careers of a plethora of researchers who would subsequently establish themselves as leaders in the global cancer research community.

Baltimore served in distinguished leadership roles throughout his storied career, including as president of Rockefeller University and later of the California Institute of Technology (Caltech), where he guided the institution through a decade of growth and scientific excellence. At Caltech, he held the Robert Andrews Millikan Professorship of Biology, and later the Judge Shirley Hufstedler Professorship of Biology, titles that underscored his standing as both a scientist and mentor with an enduring legacy.

Beyond the laboratory and university walls, Baltimore’s voice carried weight in national and international science policy forums. He was a leading advocate for federal investment in AIDS research, co-chaired the National Academy of Sciences Committee on a National Strategy for AIDS in 1986, and led the NIH AIDS Vaccine Research Committee a decade later. He also played an active role in shaping consensus guidelines on genetic engineering, thereby ensuring that scientific innovation proceeded with ethical responsibility.

Throughout his lifetime, Baltimore received innumerable honors, including election to the National Academy of Sciences, the Institute of Medicine, and the American Academy of Arts and Sciences. He was recognized with the National Medal of Science, the AMA Scientific Achievement Award, and the Lasker-Koshland Special Achievement Award in Medical Science. He also served as president of the American Association for the Advancement of Science and was elected to the inaugural class of Fellows of the AACR Academy in 2013.

Perhaps as significant as his discoveries, was Baltimore’s role as a mentor. He trained and inspired generations of scientists who themselves went on to make landmark contributions in cancer biology, immunology, and virology. Many of his mentees later achieved the highest levels of recognition in the field, including election as Fellows of the AACR Academy. His intellectual generosity and willingness to champion young investigators created a legacy of discovery that continues to reverberate to this day and will help to advance future researchers in the years to come.

David Baltimore’s life was one of restless inquiry, bold imagination, and unwavering dedication to science. His revolutionary discoveries continue to transform cancer medicine and deepen our understanding of life itself. The cancer research community—and indeed, all of biomedical science—mourns the loss of one of its most visionary and impactful leaders.

Share this:

• X
• LinkedIn
• Facebook
• Print
• Email

Like this:

Like Loading...

Posted in CANCER BIOLOGY & Innovations in Cancer Therapy, Nobel Prize Winners, Oncolytic virus & OncoViro-Therapy, RNA Biology, Cancer and Therapeutics, virology | Tagged BCR-ABL, human immunodeficiency virus (HIV), nobel leureates, Nobel Prize in Physiology and Medicine, retrovirus, reverse transcriptase, RNA virus, tumor virus, tumorigenicity, viral oncogenesis | Leave a Comment »

Real Time Conference Coverage: Advancing Precision Medicine Conference, Afternoon Session October 4 2025

October 4, 2025 by sjwilliamspa

Real Time Conference Coverage: Advancing Precision Medicine Conference, Afternoon Session  October 4 2025

Reporter: Stephen J. Williams, PhD

Leaders in Pharmaceutical Business Intellegence will be covering this conference LIVE over X.com at

@pharma_BI

@StephenJWillia2

@AVIVA1950

@AdvancingPM

using the following meeting hashtags

#AdvancingPM #precisionmedicine #WINSYMPO2025

1:40 – 2:30

AI in Precision Medicine

Dr. Ganhui Lan VP, Data Science & Machine Learning, Genentech

Dr. Xiaoyan Wang Research Professor, Department of Health Policy and Management, Tulane University Chief Scientist, SVP, Intelligent Medical Objects

Dr. Ahmad P. Tafti Assistant Professor, School of Computing and Information,School of Health and Rehabilitation Sciences, University of Pittsburgh Interim Director, Division of Scientific Affairs, Computational Pathology AI Center of Excellence

Jen Gilburg (moderator)Deputy Secretary of Technology and Entrepreneurship, Dept. of Community and Economic Development, Commonwealth of Pennsylvania

• AI will help reduce time for drug development especially in early phase of discovery but eventually help in all phases
• Ganhui: for drug regulators might be more amenable to AI in clinical trials; AI may be used differently by clinicians
• nonprofit in Philadelphia using AI to repurpose drugs (this site has posted on this and article will be included here)
• Ganhui: top challenge of AI in Pharma; rapid evolution of AI and have to have core understanding of your needs and dependencies; realistic view of what can be done; AI has to have iterative learning; also huge vertical challenge meaning how can we allign the use of AI through the healthcare vertical layer chain like clinicians, payers, etc.
• Ganhui sees a challenge for health companies to understand how to use AI in business to technology; AI in AI companies is different need than AI in healthcare companies
• 95% of AI projects not successful because most projects are very discrete use

2:00-2:20

Building Precision Oncology Infrastructure in Low- and Middle-Income Countries

Sewanti Limaye, MD, Director, Medical & Precision Oncology; Director Clinical and Translational Oncology Research, Sir HN Reliance Foundation Hospital & Research Centre, Mumbai, India; Founder, Nova Precision AI; Co-Founder, Iylon Precision Oncology; Co-Chair, Asia Pacific Coalition Against Lung Cancer; Co-Chair,  Asia Pacific Immuno-Oncology; Member,  WIN Consortium

• globally 60 precision initiatives but there really are because many in small countries
• three out of five individuals in India die of cancer
• precision medicine is a must and a hub and spoke model is needed in these places; Italy does this hub and spoke; spokes you enable the small places and bring them into the network so they know how and have access to precision medicine
• in low income countries the challenge starts with biopsy: then diagnosis and biomarker is issue; then treatment decision a problem as they may not have access to molecular tumor boards
• prevention is always a difficult task in LMICs (low income)
• you have ten times more patients in India than in US (triage can be insurmountable)
• ICGA Foundation: Indian Cancer Genome Atlas
• in India mutational frequencies vary with geographical borders like EGFR mutations or KRAS mutations
• genomic landscape of ovarian cancer in India totally different than in TCGA data
• even different pathways are altered in ovarian cancer seen in North America than in India
• MAY mean that biomarker panels need to be adjusted based on countries used in
• the molecular data has to be curated for the India cases to be submitted to a tumor board
• twenty diagnostic tests in market like TruCheck for Indian market; uses liquid biopsy
• they are also tailoring diagnostic and treatment for India getting FDA fast track approvals

2:20-2:40

Co-targeting KIT/PDGRFA and Genomic Integrity in Gastrointestinal Stromal Tumors

Lori Rink, PhD, Associate Professor, Fox Chase Cancer Center

• GIST are most common nesychymal tumor in GI tract
• used to be misdiagnosed; was considered a leimyosarcoma
• very asymptomatic tumors and not good prognosis
• very refractory to genotoxic therapies
• RTK KIT/PDGFRA gain of function mutations
• Gleevec imatinib for unresectable GIST however vast majority of even responders become resistant to therapy and cancer returns
• there is a mutation map for hotspot mutations and sensitivity for gleevec
• however resistance emerged to ripretinib; in ATP binding pocket
• over treatment get a polyclonal resistance
• performed a kinome analysis; Wee1 looked like a potential target
• mouse studies (80 day) showed good efficacy
• avapiritinib ahs some neurotox and used in PDGFRA mut GIST model which is resistant to imitinib
• but if use Wee1 inhibitor with TKI can lower dose of avapiritinib
• cotargeting KIT/PDGFRA and WEE1 increases replicative stress
• they are using PDX models to test these combinations
• combination creates genomic instability

 

Share this:

• X
• LinkedIn
• Facebook
• Print
• Email

Like this:

Like Loading...

Posted in Artificial Intelligence - Breakthroughs in Theories and Technologies, Artificial Intelligence Applications in Health Care, Artificial Intelligence in CANCER, Artificial Intelligence in Medicine - Application for Diagnosis, Artificial Intelligence in Medicine - Applications in Therapeutics, Bio-Ethics, BioBanking, BioIT: BioInformatics, BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics, Biological Networks, Biological Networks, Gene Regulation and Evolution, Cancer Genomics, Cancer Informatics, Clinical Diagnostics, Foundations for supporting Science and Education, Gene Regulation, Health Care System by Country, India, Intelligent Information Systems, Machine Learning, Natural Language Processing (NLP), Personalized and Precision Medicine & Genomic Research, Personalized Medicine Coalition, Precision Cancer Medicine, Proteomics, REAL TIME Conference Coverage Twitter's Hashtags and Handles per Presentation/session, Scientific & Biotech Conferences: Press Coverage, tumor microenvironment | Tagged access to care, AI in Healthcare, Artificial Intelligence & Clinical Trials, Artificial Intelligence ( AI), artificial intelligence in drug design, bioethics, Biomarker discovery, biomarker panels, biomarkers panels, cancer centers, cancer consortium, cancer diagnostics, deep learning in drug discovery, Fox Chase Cancer Center, gastrointestinal carcinomas, Genentech, health disparities, healthcare delivery, immunooncology, India, molecular tumor board, Predictive Cancer Biomarkers | Leave a Comment »

Real Time Conference Coverage: Advancing Precision Medicine Conference, Late Morning Session Track 1 October 4 2025

October 4, 2025 by sjwilliamspa

Real Time Conference Coverage: Advancing Precision Medicine Conference, Late Morning Session Track 1 October 4 2025

Reporter: Stephen J. Williams, PhD

Leaders in Pharmaceutical Business Intellegence will be covering this conference LIVE over X.com at

@pharma_BI

@StephenJWillia2

@AVIVA1950

@AdvancingPM

using the following meeting hashtags

#AdvancingPM #precisionmedicine #WINSYMPO2025

SESSION 3

Advances in Precision Oncology:
From Genomics to Targeted Therapies

11:10-11:55

Breaking the Glass Ceiling: Targeting KRAS in Pancreatic Cancer

Michael Pishvaian, MD, Associate Professor, Department of Oncology, Johns Hopkins University

Kim Reiss, MD, Associate Professor of Medicine (Hematology-Oncology), Hospital of the University of Pennsylvania

11:55-12:15

Charting the Future of Cancer Care: Precision Oncology and the Power of Genomics

Vivek Subbiah, MD,
Chief, Early-Phase Drug Development, Sarah Cannon Research Institute

12:15-12:35

Molecular Pathology as a Driver of Precision in Urological Cancers

Liang Cheng, MD, Professor and Vice Chair, Translational Research; Director of Anatomic and Molecular Pathology, Department of Pathology and Laboratory Medicine, Brown University Medical School, Lifespan Academic Medical Center

 

12:30-12:40

Non – CME – dSTRIDE™-HR: A Functional Biomarker for In Situ, ‘real-time’ Detection and Quantification of Homologous Recombination Activity.

Magda Kordon-Kiszala, PhD, CEO and co-founder, intoDNA

12:35-12:55

Epigenetic Plasticity and Tumor Evolution: Mechanisms of Resistance in Precision Oncology

Johnathan R. Whetstine, PhD, Director, Cancer Epigenetics Institute, Director, Geonomics Resource, Fox Chase Cancer Center

• Title: Epigenetic plasticity a gatekeeper to generating extrachromosomal DNA amplification and rearrangements
• genetic events in cancer are actually controlled not random as he says
• Fox Chase Cancer Center Epigenetics Institute; 5th year goal to understand epigenetic mechanisms to understand resistance and biomarker development; bring others and break down silos;  they are expanding and hiring and bringing into a network; March 5 2026 5th Annual Symposium Philadelphia Franklin Institute
• DNA amplification is also chromosomal: integrated same locus or different regions or chromosomal duplication
• KDM4A epigenetic demethylase controls transiet site specific DNA re-replication; can have focal control of DNA regions
• you can control regional control of like EGFR amplification
• can use Cy3 to find local regions
• KDM3B inhibitor promotes transiet copy gains in KMT2A/MLL
• EHMT2 is lysine demethylase is a driver of this copy amplification
• this demethylase can change expression locally in one hour.. very fast
• demethylases are very specific for their gene locus they control and so this demethylase only controls MLL gene
• doxorubicin topoisomerase inhibitor can cause LOH in MLL locus and methylase inhibitor can reverse this
• over twenty combinatorial regulators so this field is just budding

11:30-12:30

Companion Diagnostics in Hereditary and Chronic Diseases – Development, Regulatory Approval, and Commercialization – Non-CME Discussion

Huw Ricketts PhD, Senior Director, CLIA Business Development, QIAGEN

Tricia Carrigan, PhD, BC Biosolutions

Arushi Agarwal, MS,  Partner, Health Advances

Melissa Reuter, MS, MBA, Director, Precision Medicine Program Strategy, GSK

• This is a session panel Discussion on the current state of companion diagnostic development, not just in oncology.  Regulatory aspects will be discussed
• Arushi: There are alot of opportunities in non-oncology areas for companion diagnostics, and time to development may be an obstacle
• Huw Rickets:  From a development standpoint most people are not looking at the diagnostic side but more on the therapeutic side.
• Tricia:  There needs to be a shift in oncology drug development world, and pharma sees developing diagnostic is too expensive.
• Meliisa: They try to engage early with the agencies to understand the regulatory landscape; GSK is very strong in their oncology platform but there are gaps in diagnostics and non-oncology programs
• Arushi: seems in Pharma oncology and non-oncology programs seems siloed
• for non-oncology many of the biomarkers may be rare… well under 25% of population
• Huw: Qiagen trying to develop diagnostics for Parkinson’s but those rare genetic diseases are easier to develop
• Arushi: neurodegenerative, NASH, and immuno diseases are big areas where companies are looking to make companion diagnostics
• Huw: kidney  disease is a big focus to develop companion diagnostics for

 

12:30-12:40

Non – CME – dSTRIDE™-HR: A Functional Biomarker for In Situ, ‘real-time’ Detection and Quantification of Homologous Recombination Activity.

Magda Kordon-Kiszala, PhD, CEO and co-founder, intoDNA

Share this:

• X
• LinkedIn
• Facebook
• Print
• Email

Like this:

Like Loading...

Posted in CANCER BIOLOGY & Innovations in Cancer Therapy, Cancer Genomics, Clinical & Translational, Clinical Diagnostics, Clinical Genomics, Conference Coverage with Social Media, FDA Regulatory Affairs, Genomic Expression, Genomic Testing: Methodology for Diagnosis, Healthcare costs and reimbursement, KRAS Mutation, Methylation, Personalized and Precision Medicine & Genomic Research, Precision Cancer Medicine, REAL TIME Conference Coverage Twitter's Hashtags and Handles per Presentation/session, TP53 - Germline mutations | Tagged anticancer drug resistance, biomarker panels, biomarker/companion diagnostics, Biomarkers & Medical Diagnostics, chemotherapy resistance, Commercialization, companion diagnostics, DNA methyation, Epigenetics, GlaxoSmithKline, precision oncology, Qiagen | Leave a Comment »

« Newer Posts - Older Posts »

• Follow Blog via Email

  Enter your email address to follow this blog and receive notifications of new posts by email.

  Email Address

  Follow

  Join 2,056 other subscribers

• Recent Posts

  • Grok thinks like PhDs – Hybrid Model for Autonomous Update of Doctoral Dissertations with Original PhD Student Author editing and acceptance of Grok’s updated output. 3rd Joint article, a pilot study for Validation of an Autonomous Journal Articles Updating System (AJAUS) tested on Autonomous Update of Aviva Lev-Ari, PhD, RN Doctoral Thesis, UB, Berkeley, 1983. January 31, 2026
  • 2026 World Economic Forum, 1/19 – 1/23/2026, Davos, Switzerland, LPBI Group’s KOLs interpretation of AI in Health Videos January 24, 2026
  • Evolving LPBI Group’s Portfolio of Intellectual Properties (IP): From 2021 Vision to 2026 Reality January 12, 2026
  • Aviva Lev-Ari, PhD, RN – Biography ->> Grokepedia Entry January 11, 2026
  • List of Articles included in the Article SELECTION from Collection of Aviva Lev-Ari, PhD, RN Scientific Articles on PULSE on LinkedIn.com for Training Small Language Models (SLMs) in Domain-aware Content of Medical, Pharmaceutical, Life Sciences and Healthcare by 15 Subjects Matter January 10, 2026
  • Article SELECTION from Collection of Aviva Lev-Ari, PhD, RN Scientific Articles on PULSE on LinkedIn.com for Training Small Language Models (SLMs) in Domain-aware Content of Medical, Pharmaceutical, Life Sciences and Healthcare by 15 Subjects Matter January 10, 2026
  • Collection of Aviva Lev-Ari, PhD, RN Scientific Articles on PULSE on LinkedIn.com January 10, 2026
  • The youngest leader in AI in Health: Tanishq Mathew Abraham, Ph.D. (@iScienceLuvr) January 8, 2026
  • 2026 Grok Multimodal Causal Reasoning on Proprietary Cariovascular Corpus: From 2021 Wolfram NLP Baseline to Thousands of Novel Relationships – A Second Head-to-Head Validation of LPBI’s Domain-Aware Training Advantage January 6, 2026
  • Workflow for Dynamic Linkage and Transition between two Authoring Systems: LPBI Group’s WordPress.com Multi-Authors Authoring System and Microsoft PowerPoint product for Slide show presentation – Part 10.1 in Composition of Methods January 6, 2026

• Archives

  Archives Select Month January 2026  (10) December 2025  (8) November 2025  (8) October 2025  (12) September 2025  (2) July 2025  (4) June 2025  (8) May 2025  (4) April 2025  (2) March 2025  (1) February 2025  (2) January 2025  (3) December 2024  (1) November 2024  (5) October 2024  (7) September 2024  (7) August 2024  (1) June 2024  (1) May 2024  (2) April 2024  (2) January 2024  (1) November 2023  (1) October 2023  (3) September 2023  (3) August 2023  (2) July 2023  (2) June 2023  (7) May 2023  (4) April 2023  (2) March 2023  (5) February 2023  (2) January 2023  (3) December 2022  (2) October 2022  (6) September 2022  (2) August 2022  (1) July 2022  (3) June 2022  (3) May 2022  (8) April 2022  (10) March 2022  (7) February 2022  (7) January 2022  (3) December 2021  (3) November 2021  (4) October 2021  (11) September 2021  (5) August 2021  (8) July 2021  (21) June 2021  (8) May 2021  (10) April 2021  (8) March 2021  (15) February 2021  (17) January 2021  (20) December 2020  (10) November 2020  (12) October 2020  (26) September 2020  (17) August 2020  (22) July 2020  (27) June 2020  (33) May 2020  (26) April 2020  (42) March 2020  (22) February 2020  (11) January 2020  (7) December 2019  (20) November 2019  (13) October 2019  (11) September 2019  (3) August 2019  (8) July 2019  (25) June 2019  (47) May 2019  (40) April 2019  (27) March 2019  (29) February 2019  (17) January 2019  (50) December 2018  (14) November 2018  (17) October 2018  (18) September 2018  (17) August 2018  (8) July 2018  (20) June 2018  (22) May 2018  (17) April 2018  (12) March 2018  (20) February 2018  (26) January 2018  (16) December 2017  (6) November 2017  (20) October 2017  (13) September 2017  (16) August 2017  (16) July 2017  (19) June 2017  (20) May 2017  (32) April 2017  (21) March 2017  (10) February 2017  (24) January 2017  (21) December 2016  (43) November 2016  (8) October 2016  (40) September 2016  (67) August 2016  (59) July 2016  (75) June 2016  (37) May 2016  (95) April 2016  (152) March 2016  (175) February 2016  (196) January 2016  (139) December 2015  (90) November 2015  (287) October 2015  (237) September 2015  (115) August 2015  (96) July 2015  (63) June 2015  (44) May 2015  (53) April 2015  (76) March 2015  (95) February 2015  (83) January 2015  (75) December 2014  (75) November 2014  (88) October 2014  (135) September 2014  (117) August 2014  (88) July 2014  (88) June 2014  (109) May 2014  (60) April 2014  (85) March 2014  (58) February 2014  (72) January 2014  (107) December 2013  (104) November 2013  (136) October 2013  (62) September 2013  (32) August 2013  (46) July 2013  (74) June 2013  (110) May 2013  (112) April 2013  (86) March 2013  (92) February 2013  (63) January 2013  (63) December 2012  (46) November 2012  (71) October 2012  (84) September 2012  (82) August 2012  (122) July 2012  (59) June 2012  (34) May 2012  (46) April 2012  (2)

• Categories

  Categories Select Category 3D Printing for Medical Application  (239)    3D Plotting Scaffolds  (44)    BioInks  (34)       Biopolymer Blend Open Porous  (18)       Dental Applications  (10)    BioPrinting in Regenerative Medicine  (77)       Cell Level  (16)       MicroEngineering Cell-Tissue & Systems  (31)       Tissue Engineering  (37)    Cardiovascular and Vascular Systems  (30)       Artificial Vascular Structures  (9)       Cardiovascular Tissue  (8)    Drug Development using MultiOrgan Chip  (11)    Drug Development/Formulation using 3D Printing  (10)    MEMS  (16)       Bio-MEMS  (12)    Organ-on-a-Chip  (11)    Programmable Sensors (Carbon Nano Tubes)  (5) 3rd Party IP: Drug DIscovery  (1) 4D Printing and Meta Materials  (10) Academic Publishing  (223)    Key Opinion Leaders in eScientific Publishing – Interviews with  (8) Advanced Drug Manufacturing Technology  (96)    Antimalarial Preparation  (8)    Autologous Cell Therapy  (14)    Automated Cell Processing  (13) Allergy and Infectious Diseases  (12) Alzheimer’s Disease  (163)    Etiology  (77)    Medical Device Therapies for Altzheimer’s Disease  (15)    Pharmacotherapy and Cell Activity  (51) Anticancer Resistance  (31) Art Exhibits on the Human Condition  (1) Art Inspires Science  (4) Article Type  (2)    Authored  (1)    Curated  (2)    Scientific report  (1) Artificial Heart  (2) Artificial Intelligence – General  (232)    An executive’s guide to AI  (10)    Artificial Intelligence – Breakthroughs in Theories and Technologies  (115)    Artificial Intelligence Applications in Health Care  (125)       Artificial Intelligence in CANCER  (39)       Artificial Intelligence in Health Care – Tools & Innovations  (74)    Artificial Intelligence in Medicine – Application for Diagnosis  (69)       Artificial intelligence applications for cardiology  (31)          AI-assisted Cardiac MRI  (10)       Artificial Intelligence in Psychiatry  (6)       Deep Learning in Pathology  (18)    Artificial Intelligence in Medicine – Applications in Therapeutics  (64)    ChatGPT, GPT-4  (7)       ChatGPT at LPBI Group  (3)       ChatGPT in Academic Education  (3)    Machine Learning  (71)       Deep Learning  (25)       Natural Language Processing (NLP)  (45)    Machine learning in predicting type 2 diabetes  (5) Auditory and vision  (13) Autism Spectrum Disorders  (10) Autoimmune Inflammatory DIseases  (24)    Crohn’s disease  (5)    Tolerance-inducing Autoimmune Disease Therapeutics  (6)    Ulcerative Colitis  (3) Autophagosome  (4) Bacterial Resistance  (25) Behavior  (26) Behavioral Genetics  (21) Big Data  (88)    Intelligent Information Systems  (51) Bio Instrumentation in Experimental Life Sciences Research  (368)    Analytical Instruments Industry  (5)    Microfuidics  (8) Bio-Ethics  (15) BioBanking  (36) Biodegradable Drug-eluting Material  (8) Bioengineering & reverse engineering design  (43) BioIT: BioInformatics  (147) BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics  (135)    Advanced Computing Platform  (32)       Blockchain Transactions System  (6)          Platform for Content Monetization embedded Content Promotion  (1)    Pancreatic adenocarcinoma classifier  (4)    Simulation Modeling in NGS  (5) Biological Engineering  (43) Biological Networks  (193) Biological Networks, Gene Regulation and Evolution  (479)    Virology  (10) Biomarkers & Medical Diagnostics  (571)    VOC – Volatile Organic Compounds as BioMarkers  (2) Biomedical Measurement Science  (173) BioSimilars  (112) BioTechnology – Venture Creation  (131)    Foundations for supporting Science and Education  (14)    Philanthropy to Academic Institution  (3) BioTechnology – Venture Creation, Venture Capital  (108)    Seeking Talent  (3) BiVAD  (1) Blindness  (6) Bone Disease and Musculoskeletal Disease  (82) Brain Basis of Emotion  (5) Business Career Consideration  (1) Ca2+ triggered activation  (61) Calcium  (21) Calcium Signaling  (71) Calmodulin Kinase and Contraction  (36) Cancer – General  (186) Cancer and Current Therapeutics  (411)    interventional oncology  (49)       Breast Cancer – impalpable breast lesions  (20)       Prostate Cancer: Monitoring vs Treatment  (9) CANCER BIOLOGY & Innovations in Cancer Therapy  (1,122)    Anaerobic Glycolysis  (51)    Cachexia  (18)    Cancer Genomics  (84)       Circulating Tumor Cells (CTC)  (27)          Liquid Biopsy Chip detects an array of metastatic cancer cell markers in blood  (17)             mRNA  (6)          MagSifter chip  (1)       KRAS Mutation  (9)       Li-fraumeni syndrome.  (3)       TP53 – Germline mutations  (8)    cancer metabolism  (28)    Funding Opportunities for Cancer Research  (12)    Genomic Expression  (150)    Glioblastoma  (7)    Hexokinase  (14)    Loss of function gene  (18)    Metabolic Immuno-Oncology  (21)    Metastasis Process  (15)    Methylation  (33)    Microbiome and Responses to Cancer Therapy  (10)    Monoclonal Immunotherapy  (29)    mtDNA  (13)    Oxidative phosphorylation  (56)    Pancreatic cancer  (10)    Pyruvate Kinase  (27)    The NCI Formulary  (1)    tumor microenvironment  (16)    Warburg effect  (50) Cancer Informatics  (104) Cancer Prevention: Research & Programs  (131) Cancer Screening  (108) Cancer Vaccines: Targeting Cancer Genes for Immunotherapy  (30)    Engineering Enhanced Cancer Vaccines  (3) cancer-general  (6) Cardiac and Cardiovascular Surgical Procedures  (328)    Aortic Valve: TAVR, TAVI vs Open Heart Surgery  (91)       Prosthesis-Patient Mismatch (PPM) in TAVI vs SAVR  (2)       TAVI vs Open Heart Surgery  (6)       Transcatheter Aortic Valve Replacement via the Transcarotid Access  (3)       Transcaval TAVR Procedure  (3)       Valve-in-Valve Procedure  (5)    Atrial Fibrilation (a-Fib), Cardiac Pacing and Arrhythmias  (18)    BackBeat’s Cardiac Neuromodulation Therapy (CNT) bioelectronic therapy  (1)    CABG  (47)    Cancer Surgery of the Heart  (10)    Cardiovascular Fluid Management: algorithms  (1)    Heart Transplant  (16)    Heart-Lung Transplant  (11)    Implantation  (3)    Left Main Coronary Artery Disease (LMCAD)  (3)    Mechanical Assist Devices: LVAD, RVAD, BiVAD, Artificial Heart  (22)    Mitral Valve: Repair and Replacement  (64)       TMVR – Transcatheter Mitral Valve Repair  (5)    PCI  (108)       Bioresorbable Vascular Scaffold (BVS)  (4)       Invasive FFR for PCI  (2)       Multivessel PCI FFR Guidance  (1)       Robotic-assisted percutaneous coronary intervention  (2)       Stent Retriever in endovascular thrombectomy  (3)    Peripheral Arterial Disease & Peripheral Vascular Surgery  (65)       Abdominal Aorta  (20)       Carotid Artery  (15)       Limb ischemia  (4)       Thoracic Aorta  (16)    Pulmonary Valve Replacement and Repair  (3)    Renal Denervation  (20)    Replacement  (1)    Robotically assisted Cardiothoracic Surgery  (2)    Tricuspid Valve Repair  (7)    Vena Caval Filters: Device for Prevention of Pulmonary Embolism and Thrombosis  (2) Cardiovascular Pharmacogenomics  (171) Cargo  (3) Cell Biology  (323) Cell Biology, Signaling & Cell Circuits  (672)    Apoptosis  (17)    Autophagy-Modulating Proteins  (6)    “Antibody–enzyme conjugates”  (6)    Cell Processing System in Cell Therapy Process Development  (27)    Endoplasmic reticulum  (3)    Enzymatic mechanism underlying the synthesis of adenosine triphosphate (ATP)  (3)    Ubiquitin  (11) Cerebrovascular and Neurodegenerative Diseases  (123)    Stroke  (9) Chemical Biology and its relations to Metabolic Disease  (464)    #BIGAxisSummit  (1)    Gut Microbiome and Obesity  (8) Chemical Genetics  (350) Child and Adolescent Psychiatry  (13) Childhood cancer  (17) Childhood malnutrition  (3) children  (3) Circulating Progenitor Cells  (27)    Bone marrow derived cells  (17)    Endothelial cells  (7)    Umbilical cord cells  (6) Clinical & Translational  (238) Clinical Diagnostics  (220)    Mass automation of plasma proteins  (13) Clinical Genomics  (144) Coagulation Therapy and Internal Bleeding  (83) Cognition  (47) Commercialization  (20) Components and IRB related issues  (4) Computational Biology/Systems and Bioinformatics  (470)    Computational Histopathology  (3)    Meta-analysis of transcriptome data  (10) Conference Coverage with Social Media  (494)    MassBio  (3) coronavirus  (18) COVID-19  (20) CRISPR/Cas9 & Gene Editing  (192)    CRISPR alternative for editing genes without cutting  (14)       CAST – Alternative to CRISPR/Cas9  (3)       Transposon-encoded CRISPR–Cas systems direct RNA-guided DNA integration  (4)    CRISPR applied to Human Germ Line  (13)       Gene Editing Impact on Longevity  (6) CT  (20) Cytokines  (20) Cytoskeleton  (85) Developmental biology  (107) Diabetes Mellitus  (146)    Artificial Pancreas for Type 2 Diabetes  (4)    Artificial Pancreas for Type1 Diabetes  (8)    Gestational diabetes  (5) Diagnostic Immunology  (61) Diagnostics and Lab Tests  (128)    Liquid Biopsy: Circulating Tumor Cells in Urine and Blood  (9) Digital HealthCare – biotech & internet joint ventures  (47) Disease Biology  (334) Disease Biology, Small Molecules in Development of Therapeutic Drugs  (487) DNA repair  (73)    Apoptosis  (13)    Autophagy  (13)    Cell death pathways  (19)    Proteolysis  (8)    Proteosome  (8) Drug Delivery Platform Technology  (157)    Drug Carrier Design  (21)       Medication Remote Compliance Monitoring  (3)    Exosomes: Natural Carriers for siRNA Delivery  (9) Drug Toxicity  (74) Ecosystems & Industrial Concentration in the Medical Device Sector  (172)    Cardiac & Vascular Repair Tools Subsegment  (128)    Exec Compensation in the Cardiac & Vascular Repair Tools Subsegment  (14)    Massachusetts Niche Suppliers and National Leaders  (20) Electronic Health Record  (10) Embryology  (24) Empathy  (6) Endocrine Diseases  (60) Enzyme Induction  (46)    ion-transporting enzyme  (2)    K + -ATPase.  (1)    Na +  (2) Epigenetics and Environmental Factors  (35) Ethics and Leadership  (10) Executive Compensation – Big Pharma  (3) Fat soluble vitamins  (4) FDA  (71) FDA Regulatory Affairs  (358)    FDA, CE Mark & Global Regulatory Affairs: process management and strategic planning – GCP, GLP, ISO 14155  (52)    ISO 10993 for Product Registration: FDA & CE Mark for Development of Medical Devices and Diagnostics  (30) Fetal Ultrasound  (2) Fiction and medicine  (5) Frontiers in Cardiology and Cardiovascular Disorders  (929)    Acute Myocardial Infarction  (63)       Cardiogenic Shock  (5)    Anemia in CVD Patients  (6)    Cardio-Oncology  (4)    Cardiomyopathy  (57)    Cardiovascular Research  (187)       Myocardial metabolism, Myocardial ischemia, myocardial perfusion, Myocardial adenine nucleotide metabolism  (64)       Pre-Clinical Animal Model Development  (23)    Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and Pulmonary Arterial Hypertension (PAH)  (20)    Cost of Inpatient Stay for Cardiovascular Diagnosis for Admission  (1)    Electrophysiology  (111)       Ablation Procedure vs Drug Therapy  (2)       Arrhythmia Detection with Machine Learning Algorithms  (7)       Cardiotoxic Risks of Immune Checkpoint Inhibitors  (1)       Genomic Analysis of EKG Electrophysiology Genomics  (3)       implantable cardioverter defibrillator (ICD) and External Defibrillation  (1)       implantable pacemaker  (2)       Rare heart rhythm disorders and Long QT syndrome (LQTS)  (7)    Epigenetics and Cardiovascular Risks  (57)    Heart Failure (HF)  (51)       Acute coronary syndrome  (7)       congestive heart failure  (19)       Hypertensive Disorders of Pregnancy  (1)    Medical Devices R&D and Inventions  (212)       Assist Devices: LV  (3)       RV  (1)       Stents & Tools  (90)       Valves & Tools  (67)    Origins of Cardiovascular Disease  (422)       Atherogenic Processes & Pathology  (180)       Congenital Heart Disease  (34)          Genetic Mutations in Congenital Heart Disease  (4)       inflammation independent of lipid levels  (13)       Systemic Inflammatory Diseases as CVD Risk  (12)    Pharmacotherapy of Cardiovascular Disease  (356)       HTN  (176)       HTN in Youth  (8)       Resident-cell-based  (43)       Subarachnoid Hemorrhage (SAH)  (1)       Transthyretin amyloid cardiomyopathy (ATTR-CM)  (1)    Spontaneous Coronary Artery Dissection (SCAD)  (6)    Stroke  (15)       endovascular thrombectomy  (6)    Vascular Diseases  (21)       mesenteric ischemia  (3) Future Pandemics Inform-graphics  (1) Gastroenterology  (38) Gene Regulation  (232) Gene Regulation and Evolution  (137) Genetics & Innovations in Treatment  (176) Genetics & Pharmaceutical  (203) Genome Biology  (967)    Exosomes  (25)    Gene Therapy & Gene Editing Development  (42)    mRNA Therapeutics  (20)    Mutagenesis  (27)    Single Cell Genomics  (25)    Single-cell sequencing  (20)    Variation in human protein-coding regions  (35) Genomic Endocrinology  (42) Genomic Testing: Methodology for Diagnosis  (416) Genomics Pharmacy  (40) Global Market of Medical Devices Technology  (2) Global Medical Publishers by Country  (3) Global Partnering & Biotech Investment  (47) GLP  (4) Glycobiology: Biopharmaceutical Production  (16) Glycobiology: Biopharmaceutical Production, Pharmacodynamics and Pharmacokinetics  (28) Health Care System by Country  (58)    AI Models in Healthcare  (12)    Centers for Medicare & Medicaid Services  (8)    Health in Israel  (2)    India  (1)    United States  (27)       Hospital-based Medical Innovations  (10)       Medical Recertification and Maintenance of Certification (MOC)  (1) Health Economics and Outcomes Research  (384)    Women Health  (18)       Heart and Brain Disease in Women  (3) Health Law & Patient Safety  (165)    and Bioethics  (14)    Biotechnology  (12)    Health Law Policy  (13) HealthCare IT  (138) Healthcare Reform  (117)    Accountable Care Organizations  (26)    Affordable Care Act  (29)       Repair  (1)       Repeal ACA  (1)       Replace  (1)    Federal Budget Appropriations  (26)    Healthcare costs and reimbursement  (59)    Indigent Nutrition  (14)    Medicare and Medicaid  (20)    Prescription Drugs Costs  (21)    Skilled Nursing Facilities  (6)    Technology Capital Expenses  (15)    Uninsured and Underinsured  (20) Hematology  (100)    Acute lymphocytic leukemia  (18)    Acute myelocytic leukemia  (21)    Hematopoiesis  (48)    Lymphoma  (21) History and physical exam  (6) Human aging  (27) Human Immune System in Health and in Disease  (246) Human Sensation and Cellular Transduction: Physiology and Therapeutics  (21) Image Processing/Computing  (41) Imaging-based Cancer Patient Management  (116) Immuno-Oncology & Genomics  (133)    mRNA platform in Drug DIscovery  (6) Immunodiagnostics  (139)    Cancer-Immune Interactions  (29)    CNS-Immune Interface  (5)    Neuronal Circuits  (4) Immunology  (123)    Adaptive Immune Response to Biomaterials and Tissue Repair  (13)    Antibody Responses Predict Antigen Exposure  (17)    Cytokine Receptor Structure  (8)    Human Antibody Response  (18)    Human Circulating Antibody Repertoire  (11)    Human Naive B Cell Repertoire  (8)    MHC Repertoires for Antigen Prediction  (8)    Protection Against Autoimmune Disease  (11)    Synthetic Immunology: Hacking Immune Cells  (15) Immunotherapy  (133)    CAR-T  (14)    combination immunotherapies.  (14)    Efficacy of Anti-Tumor T Cells  (13)    Engineering Better T Cells  (8)    Immune Engineering  (17)    Immune Modulatory  (15)    Integrin-targeted Combination Immunotherapy  (6)    Modulating Macrophages in Cancer Immunotherapy  (16)    NK Cell-Based Cancer Immunotherapy  (19)    Synergistic Innate and Adaptive Immunotherapy  (14) Income Disparity  (2) Infectious Disease & New Antibiotic Targets  (162)    Antibiotic resistance  (7)    Viral diseases  (37)       Myocarditis  (1) Infectious Disease Immunodiagnostics  (58)    Virology – Vector-borne DIsease  (17) Inflammasome  (29)    Anti-tumor necrosis factor drugs (TNF inhibitors)  (3) Innovation in Immunology Diagnostics  (111)    Universal Immune Cell Therapies (uICT)  (11) Innovations  (186)    R&D Expenditure  (8) Innovations in Neurophysiology & Neuropsychology  (145)    Age and Life Expectancy  (3)    autism spectrum disorder  (1)    Circadian Rhythm and Sleep  (6)    hNPCs  (1)    Nervous System Function  (2)    Relapsing Multiple Sclerosis  (1) Intellectual Property  (83)    Disputes and Settlements  (9)    IP Valuation Models – Pricing Intangible Assets  (7)    Patent Law in Biotech  (12) Intellectual Property, Innovations, Commercialization, Investment in technological breakthrough  (119) International Global Work in Pharmaceutical  (190) Interventional Oncology: Radiofrequency Ablation, Transarterial Chemoembolization, Microwave Ablation and Irreversible Electroporation (IRE)  (12) Interviews with Scientific Leaders  (315)    Albany Medical Center Prize in Medicine and Biomedical Research  (2)    Annual Breakthrough Prize  (4)    Annual Lewis S. Rosenstiel Award  (2)    Awards in Cardiology and Cardiovascular Medicine  (6)    CEOs of Biotech Companies  (3)    Gerald D Aurbach Award for Outstanding Translational Research  (2)    Interviews with Key Opinion Leaders (KOLs)  (10)    James Prize in Science and Technology Integration  (2)    Jessie Stevenson Kovalenko Medal – Medical Sciences  (2)    Lemelson-MIT Prize  (2)    Life Sciences Breakthrough Prize  (5)    Mosteller Statistician of the Year Award  (2)    Mourning the Loss of a Scientific Leader  (3)    National Academy of Sciences AWARDS  (4)    Nobel Prize Winners  (29)    Noble Prize (Not Nobel Prize)  (2)    Paul Marks Prize for Cancer Research  (2)    Russ Prize recognizes bioengineering achievements worldwide  (2)    The Dan David Prize  (6)    Warren Alpert Foundation Prize Recipients  (4)    Wolf Prize  (2)    Wolf Prize in Medicine  (2)    women in science  (5) Investment in Technological Breakthrough  (60) Ionic Transporters Na+  (25) IP Development by LPBI Group Team  (14) IP Development by LPBI Group Team & Other Organizations  (8) ISO 14155  (3) Joint Venture – SBH & M3DP: SOP and Arrangements  (1) Justice & Law  (1) K  (15) Lab-on-a-chip  (2) Landscape  (1) Lasers and photonics  (18)    Midrange IR spectroscopy  (1) Law and Medicine Conflicts  (14) Leadership, Power, Social Interlocking Connections  (13) Lipid metabolism  (109)    Fatty acids  (38)    Lipids  (38)    PCSK9 Inhibitor Therapy  (19) Lipidomics  (11) Liposome  (4) Liver & Digestive Diseases Research  (122) LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management  (143)    Award Nominations  (5)    BioMed e-Books e-Series by LPBI Group  (9)    Feedback from Investors: LPBI Portfolio of Five Businesses  (2)    LPBI Group Founder – Aviva Lev-Ari  (27)    PhD  (1)    RN  (1) LPBI Management  (23) Massachusetts Academy of Sciences (MAS)    (2) Materials Science & Engineering  (37)    Organic BioElectronics  (2) Math  (13)    Great Discoveries  (7) Mechanical Assist Devices: LVAD  (4) Medical and Population Genetics  (193) Medical Devices R&D Investment  (242)    21st Century Cures Act  (2)    CE Mark & Global Regulatory Affairs: process management and strategic planning – GCP  (14)    Rhythm management device hardware: dual-chamber pacemakers  (1)       Systolic HTN  (1) Medical Imaging Technology  (59) Medical Imaging Technology, Image Processing/Computing, MRI, CT, Nuclear Medicine, Ultra Sound  (164)    Circumferential-Intravascular-Radioluminescence-Photoacoustic-Imaging (CIRPI)  (3)    Echocardiography  (3)    MRI  (18)    Noninvasive Diagnostic Fractional Flow Reserve (FFR) CT  (6)    Ultra Sound  (10) Melatonin & Circadian Regulation  (9) memory loss  (1) Metabolism  (239)    Biochemical pathways  (144)       Enzymes and isoenzymes  (73)          Dehydrogenase  (16)          Kinase  (28)          Phosphatase  (9)          Phosphorylase  (22)          tyrosine decarboxylases  (3)    Inosine nucleotides  (9)    Leloir pathway  (6)    microbiome  (7)    Pentose monophosphate shunt  (14)    Pyridine nucleotides  (28)       Pyridine nucleotide transhydrogenase  (7) Metabolomics  (321) Methods  (37) Mg++  (10) Microbiologial genetics  (36) Microbiology  (68)    Virology  (14) Micronutrients  (16) Microvesicle  (7) Microwave Ablation and Irreversible Electroporation (IRE)  (1) Mobile Healthcare  (5) Molecular Genetics & Pharmaceutical  (377)    Organoids  (3) Monoclonal antibody therapy  (14) Mutant Gene Expression  (42) Myocardial adenine nucleotide metabolism  (6) Myocardial Ischemia  (26) Myocardial Metabolism  (36) Na-K transport  (40) Na-K-ATPase  (27) Nanotechnology for Drug Delivery  (99) Nephrology  (46) Nephrology & Regenerative medicine  (9) Neurodegenerative Diseases  (89)    hNPCs  (3)    MS  (5) Neurohumoral Transmission  (68)    Ca2+ triggered activation  (21)    Calmodulin  (13)    Parkinson’s disease dyskinesia levodopa  (3)    PKC  (13)    Synaptic vesicle  (20) Neurological Diseases  (121) Neuroscience  (126) Next Generation Sequencing (NGS)  (27)    Nanopore sequencing  (1) NIH Common Fund  (1) Nitric Oxide in Health and Disease  (136) Nuclear Medicine  (11) Nutrigenomics  (68) Nutrition  (195)    Nutritional Supplements: Atherogenesis, lipid metabolism  (50) Nutrition and Phytochemistry  (62)    Minerals in Medicine  (4)    Plant extract  (22) Nutrition Disorders  (31) Nutritional Supplements: Atherogenesis  (31) Obesity  (19) Oligonucleotide Therapeutics & Delivery  (7) Oncolytic virus & OncoViro-Therapy  (22)    Synthetic Virology  (1) Organ-on-a-Chip & 3D Printing in Life Sciences  (7) Pain: Etiology, Genetics & Innovations in Treatment  (24) Parasitology  (5)    Malaria  (4)    Tropical diseases  (1) Patents  (34) Patient Experience  (66)    Art therapy  (1)    Hospital reputation  (7)    Humor  (1)    Music therapy  (2)    Pain Alleviation  (7)    Patient Outlook  (28)    Reputation of Interventionist  (4)    Support Staff  (13)    Supportive therapies  (6)       laughfter  (1)    Surgical Procedure  (9) Patient Experience: Personal Memories of Invasive Medical Intervantion  (30) Patient’s Voice: Personal Experience with Invasive Medical Procedures  (18) Perioperative Statins at Noncardiac Surgery  (2) Personal Health Applications: Tech Innovations serves HealhCare  (43) Personalized and Precision Medicine & Genomic Research  (736)    Longevity  (3)    New Drug Approval  (5)    Patient-centered Medicine  (39)       cell-based therapy  (9)       stem cell biology and patient-specific  (7)    Personalized Medicine Coalition  (10)    Precision Cancer Medicine  (31) Phagophore  (2) Pharmaceutical Analytics  (261)    Pharmacologic toxicities  (62) Pharmaceutical Discovery  (109)    Rapid automation of plasma protein pools  (17) Pharmaceutical Drug Discovery  (200)    Drug Development Process  (55)       Drug Discovery Chemistry  (29)    drug repurposing  (10) Pharmaceutical Industry Competitive Intelligence  (343)    Pharmacovigilance  (7)    Value-based Drug Pricing  (8) Pharmaceutical R&D Informatics  (44) Pharmaceutical R&D Investment  (299) Pharmacodynamics and Pharmacokinetics  (24) Pharmacogenomics  (159) Photography Collection  (1) Physics  (12) Placenta  (7) Population genetics  (27) Population Health Management  (204)    Evolution of Biology Through Culture  (14)    U.S. Employment-to-Population Ratio  (8) Population Health Management, Genetics & Pharmaceutical  (643)    COVID-19  (157)       Biomarkers: Inflammation  (37)       Cancer Researchers Fighting COVID-19  (14)       COVID-19 effects on Human Heart  (15)       COVID-19: Pandemic Surgery Guidance  (19)       Economic Impact of Coronavirus Pandemic  (41)       number of asymptomatic infections  (27)       Treatment Protocols for COVID-19  (62)    SARS-CoV-2  (141)       Coronavirus Gene Expression  (66)          SARS-CoV-2 circulating variants   (14)          SARS-CoV-2 Viral Variants  (19)       Glycosylation and its Role in SARS-CoV-2 Viral Pathogenesis  (2)       Immune-Mediation (independent immunopathology: lung and reticuloendothelial system)  (30)       Mechanisms of infection by SARS-CoV-2  (21)       SAR-Cov-2 a vasculotropic (blood vessels) RNA Virus  (35)          SARS-COV2 Hijacking the Complement and Coagulation Systems  (19)       Seasonality & Environmental Factors in Resurgence  (26)       Serology tests for coronavirus antibodies  (44)       T-cell response to SARS-CoV-2 infection  (14)       Vaccinology  (51)          Mechanism of Thrombosis with AZ & J&J COVID-19 Vaccines  (5)       Virtual Drug Molecule Screening targeting SAR-CoV-2 proteins  (8)    Virus Infective Acute Respiratory Syndrome: SARS-CoV  (92) Population Health Management, Nutrition and Phytochemistry  (162) Preimplantation Genetic Diagnosis and Reproductive Genomics  (13) Protein-energy malnutrition  (12) Proteomics  (367)    Amino acids  (54)    Proteins  (138) Pulmonary diseases  (16)    Lung and pulmonology  (15) Pulmonary pathology  (8) Radio Frequency (RF)-based Surgical Solutions  (2) REAL TIME Conference Coverage Twitter’s Hashtags and Handles per Presentation/session  (50) Regenerative Biology and Medicine  (92) Regulated Clinical Trials: Design, Methods, Components and IRB related issues  (265) Reproductive Andrology, Embryology, Genomic Endocrinology, Preimplantation Genetic Diagnosis and Reproductive Genomics  (113) Reproductive Biology & Bio Instrumentation  (78) RNA Biology  (81)    RNA interference (RNAi) therapeutic  (4) RNA Biology, Cancer and Therapeutics  (64) RVAD  (1) SBIR, SBA, NIH, NSF  (3) Schizophrenia  (16) Scientific & Biotech Conferences: Press Coverage  (182) Scientific Publishing  (609)    Curation  (585)       Curation methodology  (40)       De novo synthesis  (16)       Dialectic  (17)       Discovery process  (72)       Evolutionary cognition  (52)       Experimental validation  (91)       Explanatory  (91)       Historical relevance  (71)       Technology Advance Assessment of  (69)       Theoretic convergence  (27)    Open Access Journals  (37) Scientist: Career considerations  (197)    Big Data & Analytics  (17)    Data Science  (13)    Women in Life Sciences  (12) Scoop.it  (19) Sensors & Analytics  (18) Sepsis  (2) Severe Autism  (3) Signaling  (102)    Phosphorylation  (43)    S-nitrosylation  (13)    Ubiquitinylation  (34) Signaling & Cell Circuits  (130) single cell sequencing  (3) Small Molecules in Development of Therapeutic Drugs  (71) Social Development  (15) Specialized 3D BioPrinters (Cornea  (1) Statistical Methods for Research Evaluation  (137) Stem Cells for Regenerative Medicine  (177)    Cardiac muscle regeneration  (19)    Competition in regenerative stem cell science  (18)    Human neural progenitor cells  (8)    Skeletal muscle regeneration  (9) STORM  (2) Stress Disorders  (19) Substance Abuse  (4) Systemic Inflammatory Response Related Disorders  (161)    Inflammatory Pathophysiology  (9) Technology Transfer: Biotech and Pharmaceutical  (354) therapeutics  (3) Tissue Engineering and Regenerative Medicine  (22) Tissue Microenvironment  (5) Transarterial Chemoembolization  (2) Transcriptomics  (47) Transformative Technologies in Healthcare  (23) Translational Science  (230)    Best evidence  (52)    Bias measurement tools  (2)    Evidence-based decision-making  (29)    Inferential analysis  (25)    Intra-rater error  (1)    Quality Assurance  (8)    Random Error  (2)    Systematic Error (Bias)  (6)    Total error  (2)    Translational Effectiveness  (49)    Translational Research  (92) Trends in Global Economy  (6) Uncategorized  (1,019) Unfolded Protein Response (UPR)  (6) US and Global Economy: Trends and Findings  (9) Venture Capital  (47)    Income Geographic Distribution  (3)    Institutional Capital Raised by Female Founders  (6) virology  (10) Vision  (7) Voices of Patients and Healthcare Providers  (22) Water Transporters  (8) Wearable Tech + Digital Health  (5) Anemia  (22) Neutropenia  (8) Neutrophilia  (9) Platelet count disorder  (9) Folate and B12  (7) Iron deficiency  (5) Myelodysplasia  (13) Myelofibrosis  (10)

• Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

• • 2012pharmaceutical
  • sjwilliamspa